1. Search Result
Search Result
Results for "

8-OH-DPAT

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Natural
Products

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-112061
    8-OH-DPAT
    Maximum Cited Publications
    8 Publications Verification

    8-Hydroxy-DPAT

    5-HT Receptor Neurological Disease Metabolic Disease
    8-OH-DPAT is a potent, brain-penetrant and selective 5-HT agonist, with a pIC50 of 8.19 for 5-HT1A and a Ki of 466 nM for 5-HT7; 8-OH-DPAT weakly binds to 5-HT1B (pIC50, 5.42), 5-HT (pIC50 <5).
    8-OH-DPAT
  • HY-15688
    8-OH-DPAT hydrobromide
    Maximum Cited Publications
    8 Publications Verification

    8-Hydroxy-DPAT hydrobromide

    5-HT Receptor Neurological Disease Metabolic Disease
    8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent, brain-penetrant and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site .
    8-OH-DPAT hydrobromide
  • HY-N2411
    Geissoschizine methyl ether
    1 Publications Verification

    5-HT Receptor Neurological Disease
    Geissoschizine methyl ether is an orally active, blood-brain barrier permeable alkaloid, and a partial agonist of the 5-HT1A receptor. It can be isolated from Uncaria hook. Geissoschizine methyl ether potently inhibits the binding of [ 3H]8-OH-DPAT to the 5-HT1A receptor in a concentration-dependent manner, with an IC50 of 0.904 μM. It ameliorates isolation-induced increased aggression and reduced sociability in mice. Geissoschizine methyl ether promotes oligodendrocyte differentiation and remyelination in the medial prefrontal cortex of adult mice .
    Geissoschizine methyl ether
  • HY-136621

    5-HT Receptor Neurological Disease
    5-HT1A modulator 2 hydrochloride, a derivative of 8-OH-DPAT (HY-112061), is a modulator of 5-HT1A with a Ki of 53 nM for 5-HT1A binding .
    5-HT1A modulator 2 hydrochloride
  • HY-112061R

    8-Hydroxy-DPAT (Standard)

    5-HT Receptor Reference Standards Neurological Disease
    8-OH-DPAT (Standard) is the analytical standard of 8-OH-DPAT. This product is intended for research and analytical applications. 8-OH-DPAT is a potent and selective 5-HT agonist, with a pIC50 of 8.19 for 5-HT1A and a Ki of 466 nM for 5-HT7; 8-OH-DPAT weakly binds to 5-HT1B (pIC50, 5.42), 5-HT (pIC50 <5).
    8-OH-DPAT (Standard)
  • HY-101377A

    (R)-8-Hydroxy-2-dipropylaminotetralin hydrobromide

    5-HT Receptor Neurological Disease
    R(+)-8-OH-DPAT ((R)-8-Hydroxy-2-dipropylaminotetralin) hydrobromide is a potent 5-HT1A agonist. R(+)-8-OH-DPAT potentiates SUL (HY-B1059)-induced dopamine (DA) release in the medial prefrontal cortex (mPFC) .
    R(+)-8-OH-DPAT hydrobromide
  • HY-19283

    5-HT Receptor Neurological Disease
    DU125530 is a potent and selective5-HT1A receptor antagonist with Ki values of 0.7, 890, 1200, 240, 750, 1100 nM for 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT3, respectively. DU125530 shows antidepressant effects .
    DU125530
  • HY-101377B

    S(-)-8-Hydroxy-2-dipropylaminotetralin hydrobromide

    5-HT Receptor Neurological Disease
    S(-)-8-OH-DPAT (S(-)-8-Hydroxy-2-dipropylaminotetralin) hydrobromide is an enantiomer of 8-OH-DPAT hydrobromide. 8-OH-DPAT hydrobromide is a potent, selective 5-HT1A agonist with a pIC50 of 8.19 .
    S(-)-8-OH-DPAT hydrobromide
  • HY-165624

    Drug Derivative 5-HT Receptor Neurological Disease
    LY-41 is a 2-aminotetralin (HY-W022362) derivative related to 8-OH-DPAT (HY-112061). LY-41 decreases 5-HT synthesis. LY-41 induces 5-HT motor syndrome. (R)-LY-41 and (S)-LY-41 are novel 5-HT1A receptor agonists .
    LY-41
  • HY-165624A

    Drug Isomer Drug Derivative 5-HT Receptor Neurological Disease
    (S)-LY-41, R-enantiomer of LY-41 (HY-165624), is 2-Sminotetralin (HY-W022362) derivative and 8-OH-DPAT (HY-112061) analogue. (S)-LY-41 is a potent and selective 5-HT1A receptor agonist. (S)-LY-41 can reduce the accumulation of 5-hydroxytryptophan (the precursor for 5-HT synthesis) in the rat brain induced by decarboxylase inhibitors (NSD 1015). (S)-LY-41 can lower the body temperature of rats and inhibit the escape response from the cage. (S)-LY-41 can induce the 5-HT behavioral syndrome. (S)-LY-41can be used for the research of neurological disease, such as depression and anxiety .
    (S)-LY-41
  • HY-165624B

    Drug Isomer Drug Derivative 5-HT Receptor Neurological Disease
    (R)-LY-41, R-enantiomer of LY-41 (HY-165624), is 2-Sminotetralin (HY-W022362) derivative and 8-OH-DPAT (HY-112061) analogue. (R)-LY-41 is a potent and selective 5-HT1A receptor agonist. (R)-LY-41 can reduce the accumulation of 5-hydroxytryptophan (the precursor for 5-HT synthesis) in the rat brain induced by decarboxylase inhibitors (NSD 1015). (R)-LY-41 can lower the body temperature of rats and inhibit the escape response from the cage. (R)-LY-41 can induce the 5-HT behavioral syndrome but is weaker than (S)-LY-41 (HY-165624A). (R)-LY-41 can be used for the research of neurological disease, such as depression and anxiety .
    (R)-LY-41
  • HY-137111

    5-HT Receptor PERK
    p-MPPF dihydrochloride is a selective 5-HT antagonist that dose-dependently antagonizes the reduction of phosphorylated Erk1/2 levels in the hippocampus induced by 8-OH-DPAT (HY-112061) in rats. p-MPPF dihydrochloride can be used for neurological disease research .
    p-MPPF dihydrochloride
  • HY-137111A

    5-HT Receptor PERK
    p-MPPF is a selective 5-HT antagonist that dose-dependently antagonizes the reduction of phosphorylated Erk1/2 levels in the hippocampus induced by 8-OH-DPAT (HY-112061) in rats. p-MPPF can be used for neurological disease research .
    p-MPPF
  • HY-182584

    5-HT Receptor Neurological Disease
    S 15931 is a 5-HT1A receptor inhibitor. S 15931 inhibits the late-phase hindpaw licking response induced by formalin and the abdominal writhing response induced by acetic acid in Mus musculus. S 15931 abolishes the spontaneous tail-flick response induced by 8-OH-DPAT in Rattus norvegicus and potentiates the analgesic effect of morphine. S 15931 is applicable for pain-related research .
    S 15931
  • HY-129481

    5-HT Receptor Neurological Disease
    LY 178210 (Compound 24) is a selective partial agonist of the 5-HT1A receptor, with Ki values ​​of 0.67 and 380 nM for the 5-HT1A and 5-HT1D receptors, respectively. LY 178210 has almost no activity against α₂-adrenergic receptors, 5-HT₂, and other neurotransmitter receptors. LY 178210 inhibits Foscolin-stimulated cyclase activity, but its maximum potency is lower than that of the full agonist 8-OH-DPAT (HY-112061). LY 178210 significantly reduces 5-hydroxyindoleacetic acid (5-HIAA) levels in the greater hypothalamus and increases serum corticosterone concentrations .
    LY 178210
  • HY-182677

    5-HT Receptor Dopamine Receptor Neurological Disease
    EF-7412 is a dual antagonist of the 5-HT1A receptor and dopamine D2 receptor, with Ki values of 27 nM and 22 nM, respectively. EF-7412 acts as an antagonist at both pre- and postsynaptic 5-HT1A receptor sites, blocking 8-OH-DPAT (HY-112061)-induced hypothermia, behavioral syndrome, and corticosterone elevation in vivo. EF-7412 increases hypothalamic 5-HIAA/5-HT and DOPAC/DA ratios, alters 5-HT and DA neuronal activity, and slightly decreases spontaneous motor activity. EF-7412 can be used for research on 5-HT1A/D2 receptor regulation and related neural pathways .
    EF-7412

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

 

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

 

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: